• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

晚期糖尿病肾病患者从利格列汀换用替格列汀后血糖控制和肾功能无显著变化。

No Significant Changes of Glycemic Control and Renal Function in Patients with Advanced-Stage Diabetic Kidney Disease by Switching from Linagliptin to Teneligliptin.

作者信息

Hirai Keiji, Nonaka Hiroaki, Ueda Moeka, Morino Junki, Kaneko Shohei, Minato Saori, Mutsuyoshi Yuko, Yanai Katsunori, Ishii Hiroki, Matsuyama Momoko, Kitano Taisuke, Aomatsu Akinori, Miyazawa Haruhisa, Ito Kiyonori, Ueda Yuichiro, Ookawara Susumu, Morishita Yoshiyuki

机构信息

Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

出版信息

Pragmat Obs Res. 2021 Aug 6;12:81-91. doi: 10.2147/POR.S314409. eCollection 2021.

DOI:10.2147/POR.S314409
PMID:34393541
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8354772/
Abstract

PURPOSE

We compared the efficacy of teneligliptin versus linagliptin for glycemic control and renoprotection in patients with advanced-stage diabetic kidney disease.

PATIENTS AND METHODS

Changes in the glycated hemoglobin (HbA1c), fasting blood glucose concentration, urine albumin-to-creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR) during a 12-month period were retrospectively analyzed after switching from linagliptin to teneligliptin in 13 patients with advanced-stage diabetic kidney disease (teneligliptin group). Thirteen propensity score-matched patients who were treated with linagliptin alone served as controls (linagliptin group).

RESULTS

The HbA1c, fasting blood glucose concentration, and UACR did not change during the 12-month study period in either group. The annual change rate in the eGFR did not differ between before and after baseline in either group.

CONCLUSION

Switching from linagliptin to teneligliptin may not improve glycemic control, reduce urinary protein excretion, or ameliorate the rate of renal function decline in patients with advanced-stage diabetic kidney disease. These results suggest that teneligliptin may not be more advantageous for glycemic control and renoprotection compared with linagliptin in patients with advanced-stage diabetic kidney disease.

摘要

目的

我们比较了替格列汀与利格列汀在晚期糖尿病肾病患者血糖控制和肾脏保护方面的疗效。

患者与方法

回顾性分析了13例晚期糖尿病肾病患者（替格列汀组）从利格列汀转换为替格列汀后12个月期间糖化血红蛋白（HbA1c）、空腹血糖浓度、尿白蛋白与肌酐比值（UACR）以及估算肾小球滤过率（eGFR）的变化。13例倾向评分匹配的仅接受利格列汀治疗的患者作为对照（利格列汀组）。

结果

两组在12个月研究期间HbA1c、空腹血糖浓度和UACR均未发生变化。两组基线前后eGFR的年变化率无差异。

结论

在晚期糖尿病肾病患者中，从利格列汀转换为替格列汀可能无法改善血糖控制、降低尿蛋白排泄或改善肾功能下降速率。这些结果表明，在晚期糖尿病肾病患者中，与利格列汀相比，替格列汀在血糖控制和肾脏保护方面可能并无更多优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/285e7aca0525/POR-12-81-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/d7c89f32c3a0/POR-12-81-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/6e36401a3bf7/POR-12-81-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/a8e17ddb71ca/POR-12-81-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/bbcf6c54ac6a/POR-12-81-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/66e6c45e6f2a/POR-12-81-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/da1d00501352/POR-12-81-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/285e7aca0525/POR-12-81-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/d7c89f32c3a0/POR-12-81-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/6e36401a3bf7/POR-12-81-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/a8e17ddb71ca/POR-12-81-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/bbcf6c54ac6a/POR-12-81-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/66e6c45e6f2a/POR-12-81-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/da1d00501352/POR-12-81-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ff/8354772/285e7aca0525/POR-12-81-g0007.jpg

相似文献

1
No Significant Changes of Glycemic Control and Renal Function in Patients with Advanced-Stage Diabetic Kidney Disease by Switching from Linagliptin to Teneligliptin.晚期糖尿病肾病患者从利格列汀换用替格列汀后血糖控制和肾功能无显著变化。
Pragmat Obs Res. 2021 Aug 6;12:81-91. doi: 10.2147/POR.S314409. eCollection 2021.
2
Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.老年2型糖尿病患者从利格列汀转换为替奈利汀的二肽基肽酶-4抑制剂的效果。
Diabetes Metab Syndr Obes. 2020 Nov 2;13:4113-4121. doi: 10.2147/DMSO.S267994. eCollection 2020.
3
Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study.利格列汀和替格列汀对2型糖尿病合并慢性肾脏病患者血糖控制的疗效：通过连续血糖监测进行评估；一项前瞻性研究。
Diabetol Int. 2016 Mar 9;7(4):368-374. doi: 10.1007/s13340-016-0258-y. eCollection 2016 Dec.
4
Efficacy of Yishen Huashi Granules Combined with Linagliptin Tablets on Blood Glucose and Renal Function in Patients with Type 2 Diabetic Nephropathy.益肾化湿颗粒联合利拉鲁肽片治疗 2 型糖尿病肾病患者的疗效及对血糖、肾功能的影响。
Comput Intell Neurosci. 2022 Sep 20;2022:4272520. doi: 10.1155/2022/4272520. eCollection 2022.
5
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.在肾功能受损的 2 型糖尿病患者中比较 gemigliptin 与 linagliptin 的疗效和安全性：GUARD 随机研究的 40 周扩展。
Diabetes Obes Metab. 2018 Feb;20(2):292-300. doi: 10.1111/dom.13059. Epub 2017 Sep 6.
6
Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy.替奈利肽在糖尿病肾病管理中的应用：治疗地位综述
J Clin Diagn Res. 2017 Jan;11(1):OE05-OE09. doi: 10.7860/JCDR/2017/25060.9228. Epub 2017 Jan 1.
7
Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study.替奈利汀对2型糖尿病合并慢性肾脏病患者氧化应激和内皮功能的影响：一项病例对照研究。
Cardiovasc Diabetol. 2016 May 17;15:76. doi: 10.1186/s12933-016-0396-3.
8
The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers.钠-葡萄糖协同转运蛋白2抑制剂在接受肾素-血管紧张素系统阻滞剂治疗的晚期糖尿病肾病患者中的疗效和安全性
Diabetes Metab Syndr Obes. 2020 Jan 30;13:215-225. doi: 10.2147/DMSO.S229046. eCollection 2020.
9
Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.替奈利汀在2型糖尿病合并肾功能不全患者中的安全性和有效性：上市后监测中期报告
Diabetes Ther. 2018 Jun;9(3):1083-1097. doi: 10.1007/s13300-018-0416-2. Epub 2018 Apr 10.
10
Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers.利格列汀作为附加疗法在接受肾素-血管紧张素-醛固酮系统阻滞剂治疗的晚期糖尿病肾病患者中的疗效和安全性。
Drug Target Insights. 2016 Sep 11;10:13-8. doi: 10.4137/DTI.S38339. eCollection 2016.

引用本文的文献

1
Renoprotective Action of Linagliptin Among Diabetic Kidney Disease Patients: A Systematic Review and Meta-Analysis.利格列汀对糖尿病肾病患者的肾脏保护作用：一项系统评价和荟萃分析。
Cureus. 2025 Apr 7;17(4):e81833. doi: 10.7759/cureus.81833. eCollection 2025 Apr.

本文引用的文献

1
The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.替格列汀独特的药理学和药代动力学特征：对临床实践的影响。
Drugs. 2019 May;79(7):733-750. doi: 10.1007/s40265-019-01086-0.
2
Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study.利格列汀和替格列汀对2型糖尿病合并慢性肾脏病患者血糖控制的疗效：通过连续血糖监测进行评估；一项前瞻性研究。
Diabetol Int. 2016 Mar 9;7(4):368-374. doi: 10.1007/s13340-016-0258-y. eCollection 2016 Dec.
3
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
利拉利汀对比安慰剂对伴有高心血管和肾脏风险的 2 型糖尿病成人患者主要心血管事件的影响：CARMELINA 随机临床试验。
JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269.
4
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.强化血糖控制对预防终末期肾病的长期获益： ADVANCE-ON。
Diabetes Care. 2016 May;39(5):694-700. doi: 10.2337/dc15-2322. Epub 2016 Mar 22.
5
Management of diabetes mellitus in individuals with chronic kidney disease: therapeutic perspectives and glycemic control.慢性肾脏病患者的糖尿病管理：治疗前景与血糖控制
Clinics (Sao Paulo). 2016 Jan;71(1):47-53. doi: 10.6061/clinics/2016(01)08.
6
Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis.糖尿病肾病：新的危险因素与诊断进展
Rev Diabet Stud. 2015 Spring-Summer;12(1-2):110-8. doi: 10.1900/RDS.2015.12.110. Epub 2015 Aug 10.
7
Diabetes and end-stage renal disease; a review article on new concepts.糖尿病与终末期肾病；一篇关于新概念的综述文章
J Renal Inj Prev. 2015 Jun 1;4(2):28-33. doi: 10.12861/jrip.2015.07. eCollection 2015.
8
A review of gliptins for 2014.2014 年治疗糖尿病药物西格列汀的综述。
Expert Opin Pharmacother. 2015 Jan;16(1):43-62. doi: 10.1517/14656566.2015.978289. Epub 2014 Nov 10.
9
Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction.在2型糖尿病和肾功能不全患者中，利格列汀在推荐的标准治疗基础上可降低蛋白尿。
Diabetes Care. 2013 Nov;36(11):3460-8. doi: 10.2337/dc13-0323. Epub 2013 Sep 11.
10
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.评价替格列汀（一种二肽基肽酶-4 抑制剂）在日本 2 型糖尿病患者中的疗效、安全性和剂量反应关系。
Diabetes Obes Metab. 2013 Sep;15(9):810-8. doi: 10.1111/dom.12092. Epub 2013 Apr 7.